MDxHealth, Predictive Bio Partner on Bladder Cancer Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced it has licensed certain DNA methylation biomarkers to Predictive Biosciences for the development of bladder cancer diagnostics.

Under the deal, Predictive has exclusive rights in the United States to use the biomarkers to develop the tests and will pay MDxHealth upfront and milestone payments as well as royalties on net sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.